NCT07544992 2026-04-22
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
City of Hope Medical Center
Phase 1 Not yet recruiting
Clinical Trials
10 trialsNCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06186401 2026-03-16
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Phase 1 Recruiting
NCT03389230 2026-02-04
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT01505569 2024-02-26
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT01808820 2022-07-20
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
University of Miami
Phase 1 Completed
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT02761915 2021-08-17
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
Phase 1 Completed
NCT01902771 2017-03-10
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
University of Miami
Phase 1 Terminated